主页 > 医药生命 >
【drug-news】Nature Reviews Cancer2011年1月刊PDF
目录：Research Highlights
Therapy: Multiple bypass problem for BRAF inhibition | PDF (114 K
p2 | doi:10.1038/nrc2990
Two new studies identify novel BRAF inhibitor resistance mechanisms in BRAF-V600E melanoma.
Tumorigenesis: RB, lost in progression | PDF (253 K
p3 | doi:10.1038/nrc2992
Retinoblastoma controls androgen receptor-mediated signalling through the transcription factor E2F1 in the late stages of prostate cancer.
Trial Watch
Circulating tumour cells | PDF (97 K
p3 | doi:10.1038/nrc3000
Tumour suppressors: Selective justice | PDF (222 K
p4 | doi:10.1038/nrc2987
Restoring the function of p53 in lung tumours only affects aggressively proliferating tumour cells.
Stem cells: Tumour stem cells generate vasculature | PDF (207 K
p4 | doi:10.1038/nrc2989
Stem-like cells in glioblastomas can differentiate into endothelial cells, thereby generating tumour vasculature.
In brief
Epigenetics | Therapy | Tumorigenesis | PDF (130 K
p5 | doi:10.1038/nrc2995
MicroRNA: Micro-loops in NF-κB signalling | PDF (292 K
p6 | doi:10.1038/nrc2991
Yong Li and colleagues identify a feedforward loop in which miR-301A expression in pancreatic adenocarcinoma relieves suppression of NF-κB and is in turn transactivated by NF-κB.
Stem cells: Self-sufficient | PDF (298 K
p6 | doi:10.1038/nrc2993
Paneth cells are essential for the survival of LGR5+ stem cells in crypt of the small intestine.
DNA repair: A single-edged sword? | PDF (130 K
p7 | doi:10.1038/nrc2994
Suppression of translesion synthesis can sensitize tumour cells to chemotherapy and reduce chemotherapy-induced mutagenesis.
Therapeutics: RNA device rewires cellular networks | PDF (246 K
p8 | doi:10.1038/nrc2988
Engineered RNAs are used to reprogramme the Wnt and nuclear factor-κB signalling pathways, which could be used therapeutically to control tumour cell signalling.
In the news
Old dog, new tricks | PDF (94 K
p8 | doi:10.1038/nrc2996
Top of pageReviews
The molecular biology of head and neck cancer
C. René Leemans, Boudewijn J. M. Braakhuis & Ruud H. Brakenhoff
p9 | doi:10.1038/nrc2982
Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease that often recurs, prompting the field cancerization hypothesis. This Review discusses the molecular pathology of HNSCC and how its heterogeneity can be used to classify the disease and provide a model of HNSCC development.
AbstractFull TextPDF (769 K For better or for worse: the role of Pim oncogenes in tumorigenesis
Martijn C. Nawijn, Andrej Alendar & Anton Berns
p23 | doi:10.1038/nrc2986
The Pim family of kinases actively collaborate with MYC in driving tumorigenesis. However, in several cancers the expression levels of PIMs can correlate with favourable prognostic outcome. This Review analyses the physiological and oncogenic activities of Pim kinases and their synergistic marriage with MYC, for better or for worse.
AbstractFull TextPDF (499 K Inside the human cancer tyrosine phosphatome
Sofi G. Julien, Nadia Dubé, Serge Hardy & Michel L. Tremblay
p35 | doi:10.1038/nrc2980
The protein tyrosine phosphatase (Ptp) family dephosphorylates target proteins and counters the activities of protein tyrosine kinases. Accumulating evidence indicates that some PTPs have an important role in the inhibition or control of growth, whereas some PTPs exert oncogenic functions. This Review discusses the relevance of PTPs to cancer biology and their potential as therapeutic targets.
AbstractFull TextPDF (704 K Article series: Models of cancer
Cell lineage and cell death: Caenorhabditis elegans and cancer research
Malia B. Potts & Scott Cameron
p50 | doi:10.1038/nrc2984
Genetic analyses of the normal development of the nematode Caenorhabditis elegans have revealed evolutionarily conserved mechanisms through which individual cells establish their fates, and how they make and execute the decision to survive or undergo programmed cell death. Mammalian counterparts of these pathways are co-opted by malignant cells, and studies in C.elegans are helping to identify new anticancer drugs.
AbstractFull TextPDF (373 K RNA interference in the clinic: challenges and future directions
Chad V. Pecot, George A. Calin, Robert L. Coleman, Gabriel Lopez-Berestein & Anil K. ***
p59 | doi:10.1038/nrc2966
Inherent difficulties with blocking many desirable targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a therapeutic approach. This Review explores current challenges to the development of synthetic RNAi-based therapies and considers new approaches to circumvent biological barriers.
AbstractFull TextPDF (1,031 K Top of pagePerspectives
Opinion
What is the malignant nature of human ductal carcinoma in situ?
Virginia Espina & Lance A. Liotta
p68 | doi:10.1038/nrc2950
The survival of genetically abnormal carcinoma progenitor cells in ductal carcinoma in situ lesions could be driven by the hypoxic, nutrient-deprived microenvironment. Understanding the potential survival mechanisms, such as autophagy, could provide new strategies for arresting invasion at the pre-malignant stage.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-05 00:02
医学,生命科学网